FDA Approves Axatilimab 9 mg and 22 mg Vial Sizes for Chronic GVHD
Axatilimab in 9 mg and 22 mg vial sizes are expected to launch in early February for the treatment of chronic graft-versus-host disease.
Axatilimab in 9 mg and 22 mg vial sizes are expected to launch in early February for the treatment of chronic graft-versus-host disease.
This Medical News article is an interview with study author MarÃa Villalobos-Quesada, PhD, a researcher at the National eHealth Living Lab at the Leiden University…
Alignment Healthcare is the latest Medicare Advantage (MA) insurer to accuse the Centers for Medicare & Medicaid Services (CMS) of wrongly calculating the company’s star…
Annual cancer statistics report identifies persistent racial and ethnic disparities and increases in certain cancers in women and younger adults.
Popular but pricey weight-loss drugs Ozempic and Wegovy are among the 15 medications whose prices will be subject to direct negotiations between Medicare and drug…
We’ve lost the ability to wait—and it’s breaking us. Here’s why impatience is stealing our lives and how to take back control.
Discover how hospitals are using creative solutions, from cartoon ceiling tiles to virtual reality, to improve pediatric patient experiences and address needs
That and other stories in “Five on Friday” for January 17, 2025…
In 2018, a galaxy about 270 million light-years away from Earth exhibited a major increase in activity. It quieted down again by 2020—only to dramatically…
Plans to reform elective care must avoid the trappings of over-investigation and fragmented and inappropriate care, writes Ella Hubbard “We need more activity, and less…
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…